Revision History

A new generation of blood tests claims to detect dozens of cancers and diseases from a single sample, but the largest clinical trial to date failed to meet its primary endpoint, and no test has received FDA approval. As companies race to market and Congress considers mandating Medicare coverage, independent scientists warn that commercial availability has outpaced the evidence — raising the specter of overdiagnosis harms similar to those seen with PSA screening decades ago.